• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.

作者信息

Ravi Gayathri, Gonsalves Wilson I

机构信息

Division of Hematology, Mayo Clinic, Rochester MN, USA.

Division of Hematology, Mayo Clinic, Rochester MN, USA.

出版信息

Cancer Treat Res Commun. 2021;29:100444. doi: 10.1016/j.ctarc.2021.100444. Epub 2021 Aug 4.

DOI:10.1016/j.ctarc.2021.100444
PMID:34555665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8688330/
Abstract
摘要

相似文献

1
Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤的当前诊断、风险分层及治疗模式
Cancer Treat Res Commun. 2021;29:100444. doi: 10.1016/j.ctarc.2021.100444. Epub 2021 Aug 4.
2
MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma.对于新诊断的适合移植的多发性骨髓瘤患者，MASS-4比MASS-3更适合用于预后分层。
Ann Med. 2025 Dec;57(1):2519671. doi: 10.1080/07853890.2025.2519671. Epub 2025 Jul 1.
3
Meeting report of the 4th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
J Cancer Res Clin Oncol. 2013 Nov;139(11):1807-11. doi: 10.1007/s00432-013-1468-3. Epub 2013 Jul 18.
4
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.合成期的克隆性浆细胞比例可识别出多发性骨髓瘤中一个独特的高危队列。
Blood Cancer J. 2025 Feb 18;15(1):20. doi: 10.1038/s41408-025-01232-w.
5
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.第六届海德堡骨髓瘤研讨会会议报告：多发性骨髓瘤诊断与治疗的现状及进展
J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.
6
Multiple myeloma: Every year a new standard?多发性骨髓瘤：每年都有新标准？
Hematol Oncol. 2019 Jun;37 Suppl 1(Suppl 1):62-65. doi: 10.1002/hon.2586.
7
Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.多发性骨髓瘤：用于诊断、预后及反应评估的新分期系统
Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80. doi: 10.1016/j.beha.2007.10.002.
8
Treatment of newly diagnosed multiple myeloma: advances in current therapy.初诊多发性骨髓瘤的治疗：当前疗法的进展。
Med Oncol. 2010 Jun;27 Suppl 1:S14-24. doi: 10.1007/s12032-009-9370-1. Epub 2009 Dec 25.
9
V. Smoldering multiple myeloma.
Hematol Oncol. 2015 Jun;33 Suppl 1:33-7. doi: 10.1002/hon.2213.
10
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096.

引用本文的文献

1
T-Cell Engagers In Multiple Myeloma: A Clinical Review.多发性骨髓瘤中的T细胞衔接器：临床综述
Blood Lymphat Cancer. 2025 Mar 24;15:1-10. doi: 10.2147/BLCTT.S492116. eCollection 2025.
2
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.一项评估米哚妥林联合维奈托克治疗复发/难治性急性髓系白血病患者的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性、剂量递增和扩展研究
Clin Lymphoma Myeloma Leuk. 2024 May;24(5):298-304. doi: 10.1016/j.clml.2024.01.002. Epub 2024 Jan 6.
3
Evolving progress in the management of malignant plasma cell disorders.恶性浆细胞疾病管理方面的进展演变
Cancer Treat Res Commun. 2022;32:100612. doi: 10.1016/j.ctarc.2022.100612. Epub 2022 Jul 19.

本文引用的文献

1
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.剂量/方案调整的 Rd-R 与连续 Rd 用于新诊断的老年、中危适合的多发性骨髓瘤患者。
Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.
2
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.硼替佐米、来那度胺和地塞米松（VRd）作为一线治疗多发性骨髓瘤时，硼替佐米不同给药方案的结果。
Am J Hematol. 2021 Mar 1;96(3):330-337. doi: 10.1002/ajh.26074. Epub 2021 Jan 13.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
5
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
7
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.染色体 1q 的获得与接受来那度胺、硼替佐米和地塞米松治疗的多发性骨髓瘤患者的早期进展相关。
Blood Cancer J. 2019 Nov 25;9(12):94. doi: 10.1038/s41408-019-0254-0.
8
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
9
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
10
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.自体移植、巩固和维持治疗多发性骨髓瘤：BMT CTN 0702 试验结果。
J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.